AU StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

CLINUVEL PHARMACEUTICALS LTD

10.420

-0.470-4.32%

Volume:109.46K

Turnover:1.15M

Market Cap:523.09M

PE:16.19

High:10.990

Open:10.700

Low:10.300

Close:10.890

52wk High:13.933

52wk Low:8.350

Shares:50.20M

Float Shares:41.32M

Volume Ratio:0.71

T/O Rate:0.26%

Dividend:0.05

Dividend Rate:0.48%

EPS(TTM):0.644

EPS(LYR):0.718

ROE:13.96%

ROA:10.62%

PB:2.10

PE(LYR):14.51

Loading ...

Overview Company News Filings

Clinuvel Pharmaceuticals Says FDA Removes Post-Authorization Requirement for Implant

MT Newswires Live

Clinuvel Unlikely to Seek Scenesse's Vitiligo Approval Before Phase 3 Completion, Says Jefferies

MT Newswires Live

Clinuvel Pharmaceuticals Ltd-FDA Relaxes Scenesse Postmarketing Requirement

THOMSON REUTERS

Clinuvel Pharmaceuticals Ltd - Qt Study Removed From U.S. Post-Authorization Requirements for Scenesse

THOMSON REUTERS

How Investors Are Reacting To Clinuvel Pharmaceuticals (ASX:CUV) EMA Guidance On SCENESSE Vitiligo Trial Design

Simply Wall St.

Clinuvel plans Phase III CUV107 vitiligo trial of Scenesse plus NB-UVB vs NB-UVB

BRIEF-Clinuvel Pharmaceuticals Receives Final EMA Scientific Advice For Pivotal Phase III Vitiligo Study

Clinuvel Pharmaceuticals Set for Phase 3 Vitiligo Study After Final Advice From European Medicines Agency

MT Newswires Live

Clinuvel Pharmaceuticals Ltd - Cuv107 Study to Commence in 2H 2026

THOMSON REUTERS

Clinuvel Pharmaceuticals Ltd - Receives Final Ema Scientific Advice for Pivotal Phase Iii Vitiligo Study

THOMSON REUTERS

ASX Growth Companies With High Insider Ownership April 2026

Simply Wall St.

ASX Growth Companies With High Insider Ownership For April 2026

Simply Wall St.

Clinuvel Phase III vitiligo trial tests afamelanotide with NB-UVB phototherapy

Clinuvel showcases vitiligo, photomedicine programs at American Academy of Dermatology meeting

ASX Growth Stocks With High Insider Ownership And Up To 40% Earnings Growth

Simply Wall St.

Clinuvel Pharmaceuticals Says JPMorgan Increases Stake

MT Newswires Live

ASX Growth Companies With High Insider Ownership In April 2026

Simply Wall St.

3 ASX Growth Stocks Insiders Own With Up To 90% Earnings Growth

Simply Wall St.

Australian Shares Fall Sharply; ASX Commits to Addressing Governance, Risk Management Shortcomings Flagged by ASIC

MT Newswires Live

Clinuvel Says Study Shows Repigmentation in Vitiligo Patients After 20 Weeks of Therapy With Drug Candidate; Shares Hit Eight-Year Low

MT Newswires Live

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers HK | Online Trading in stocks, bonds & ETFS","description":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","keywords":"tiger trading,tiger security,tiger broker hk,tigers co ltd,tiger trade hk,tiger brokers hk,stock broker,securities broker,online brokerage,hong kong broker,hk broker,online stock trading,online trading platform,stock trading platforms,trading application,stock trading,stock trading hong kong,buying stocks in hong kong,tiger brokers","social":{"ogDescription":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.gotigerhk.com/stock/CUV.AU/news?page=3"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental","symbol":"CUV.AU","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"CUV.AU\",,,,,undefined,":{"symbol":"CUV.AU","market":"AU","secType":"STK","nameCN":"CLINUVEL PHARMACEUTICALS LTD","latestPrice":10.42,"timestamp":1787292720000,"preClose":10.89,"halted":0,"volume":109462,"delay":0,"changeRate":-0.04315886134067958,"nameEN":"CLINUVEL PHARMACEUTICALS LTD","floatShares":41318955,"shares":50200740,"eps":0.643659,"marketStatus":"Market Closed","change":-0.47,"latestTime":"08-21 16:12:00 AEST","open":10.7,"high":10.99,"low":10.3,"amount":1153118,"amplitude":0.063361,"askPrice":10.97,"askSize":500,"bidPrice":10.3,"bidSize":325,"shortable":3,"etf":0,"ttmEps":0.643659,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":0,"beginTime":1787529600000},"marketStatusCode":7,"adr":0,"exchange":"ASX","adjPreClose":10.89,"dividendRate":0.004798,"openAndCloseTimeList":[[1787270400000,1787292000000]],"volumeRatio":0.709792966784423,"lotSize":1,"tradeCurrency":"AUD","auctionPricing":{"symbol":"CUV.AU","preClose":10.89,"auctionPrice":10.42,"auctionVolume":9329,"auction":3,"marketStatus":"盘后竞价","timestamp":1787292600774}},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"CUV.AU\",,,,,undefined,":{"symbol":"CUV.AU","floatShares":41318955,"roa":"10.62%","roe":"13.96%","lyrEps":0.717999,"volumeRatio":0.709792966784423,"shares":50200740,"dividePrice":0.05,"high":10.99,"amplitude":0.063361,"preClose":10.89,"low":10.3,"week52Low":8.35,"pbRate":"2.10","psRate":"5.43","week52High":13.933,"institutionHeld":0,"latestPrice":10.42,"committee":-0.212121,"eps":0.643659,"divideRate":0.004798,"volume":109462,"delay":0,"ttmEps":0.643659,"open":10.7,"prevYearClose":12.46,"prevWeekClose":9.55,"prevMonthClose":9.06,"prevQuarterClose":10.28,"fiveDayClose":9.55,"twentyDayClose":10.06,"sixtyDayClose":8.96,"earningDate":1787760000000,"dividendPayoutRate":0.06921842705277628,"dividendFrequency":"A","dividendGrowthYears":5,"dividendGrowthRate":0,"fiveYearAvgDividendRate":0.0025824359172833843},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/CUV.AU\",params:#limit:5,,,undefined,":[{"date":"2026-08-27","symbol":"CUV.AU","type":"earning","reportTimeType":"","market":"AU","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1787788800000,"name":null,"time":"","dateTimestamp":1787752800000,"actualEps":null},{"date":"2026-02-26","symbol":"CUV.AU","type":"earning","reportTimeType":"","market":"AU","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1772060400000,"name":null,"time":"","dateTimestamp":1772024400000,"actualEps":null},{"date":"2025-09-04","symbol":"CUV.AU","amount":0.05,"announcedDate":null,"type":"dividend","lastAmount":null,"market":"AU","newRecordDate":"2025-09-05","defaultRemindTime":1756944000000,"name":"CLINUVEL PHARMACEUTICALS LTD","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-09-19","payableDate":"2025-09-05","currency":"AUD","dateTimestamp":1756908000000,"payDate":"2025-09-19"},{"date":"2025-08-28","symbol":"CUV.AU","type":"earning","reportTimeType":"","market":"AU","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1756339200000,"name":null,"time":"","dateTimestamp":1756303200000,"actualEps":null},{"date":"2025-02-26","symbol":"CUV.AU","type":"earning","reportTimeType":"","market":"AU","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1740524400000,"name":null,"time":"","dateTimestamp":1740488400000,"actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"CUV.AU\",market:\"AU\",,,undefined,":[{"executeDate":"2020-09-03","recordDate":"2020-09-04","paymentDate":"2020-09-18","value":0.025,"currency":"AUD"},{"executeDate":"2021-09-02","recordDate":"2021-09-03","paymentDate":"2021-09-17","value":0.025,"currency":"AUD"},{"executeDate":"2022-09-06","recordDate":"2022-09-07","paymentDate":"2022-09-21","value":0.04,"currency":"AUD"},{"executeDate":"2023-09-05","recordDate":"2023-09-06","paymentDate":"2023-09-20","value":0.05,"currency":"AUD"},{"executeDate":"2024-09-05","recordDate":"2024-09-06","paymentDate":"2024-09-20","value":0.05,"currency":"AUD"}],"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"CUV.AU\",pageSize:20,pageCount:3,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2630337676","title":"Clinuvel Pharmaceuticals Says FDA Removes Post-Authorization Requirement for Implant","url":"https://stock-news.laohu8.com/highlight/detail?id=2630337676","media":"MT Newswires Live","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2630337676?lang=en_us&edition=fundamental","pubTime":"2026-04-27 08:36","pubTimestamp":1777250204,"startTime":"0","endTime":"0","summary":"Clinuvel Pharmaceuticals  said the US Food and Drug Administration  removed a requirement for a post-authorization phase one study on cardiac repolarization in relation to its Scenesse implant upon reviewing its long-term safety profile, according to a Monday filing with the Australian bourse.Scenesse is used to treat patients with erythropoietic protoporphyria, a disease that causes intolerance to light.The FDA concluded that the study was no longer needed since it would not yield valuable safety information, the filing said.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4585","CUV.AU","BK4588","BK4212","BK7067","BK7508","POST","LABU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2630333203","title":"Clinuvel Unlikely to Seek Scenesse's Vitiligo Approval Before Phase 3 Completion, Says Jefferies","url":"https://stock-news.laohu8.com/highlight/detail?id=2630333203","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2630333203?lang=en_us&edition=fundamental","pubTime":"2026-04-27 08:14","pubTimestamp":1777248895,"startTime":"0","endTime":"0","summary":"Clinuvel Pharmaceuticals  is unlikely to seek regulatory approval for Scenesse in vitiligo until the Phase 3 CUV105 and CUV107 clinical trials are completed, according to a Friday Jefferies note.The company said on Friday that the European Medicines Agency  has proposed evaluating the company's Scenesse drug for the treatment of systemic vitiligo based on a \"totality of evidence\" regulatory approach.Jefferies said that the EMA's decision is a positive for the company because of the high unmet medical need for Vitiligo treatment.The investment firm has pushed back its revenue expectations from Scenesse in vitiligo, which is now expected to begin in the second half of fiscal 2029 rather than fiscal 2028.Jefferies kept a buy rating on Clinuvel and cut its price target to AU$39.20 from AU$40.50.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["EMA","BK7129","BK7508","BK4081","BK7067","EMA.AU","CUV.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2630533105","title":"Clinuvel Pharmaceuticals Ltd-FDA Relaxes Scenesse Postmarketing Requirement","url":"https://stock-news.laohu8.com/highlight/detail?id=2630533105","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2630533105?lang=en_us&edition=fundamental","pubTime":"2026-04-27 06:42","pubTimestamp":1777243353,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260426:nTUE5ZMBJ3:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["CUV.AU","BK7067","BK7508"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2630331016","title":"Clinuvel Pharmaceuticals Ltd - Qt Study Removed From U.S. Post-Authorization Requirements for Scenesse","url":"https://stock-news.laohu8.com/highlight/detail?id=2630331016","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2630331016?lang=en_us&edition=fundamental","pubTime":"2026-04-27 06:42","pubTimestamp":1777243353,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260426:nTUE5ZMBJ3:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7508","BK7067","CUV.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2630980518","title":"How Investors Are Reacting To Clinuvel Pharmaceuticals (ASX:CUV) EMA Guidance On SCENESSE Vitiligo Trial Design","url":"https://stock-news.laohu8.com/highlight/detail?id=2630980518","media":"Simply Wall St.","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2630980518?lang=en_us&edition=fundamental","pubTime":"2026-04-25 20:10","pubTimestamp":1777119025,"startTime":"0","endTime":"0","summary":"Clinuvel Pharmaceuticals recently reported that the European Medicines Agency issued final scientific advice on its planned pivotal Phase III CUV107 trial, outlining how SCENESSE (afamelanotide) will be evaluated as a systemic treatment for non-segmental vitiligo in adults and adolescents.\nThe regulator’s “totality of evidence” approach, with T-VASI50 as the primary endpoint and strong emphasis on patient-reported and photographic outcomes, underscores both the complexity and patient-centric...","market":"us","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-cuv/clinuvel-pharmaceuticals-shares/news/how-investors-are-reacting-to-clinuvel-pharmaceuticals-asxcu-1","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-cuv/clinuvel-pharmaceuticals-shares/news/how-investors-are-reacting-to-clinuvel-pharmaceuticals-asxcu-1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK4211","BK7508","BK4543","BK4023","BK4588","BK4551","BK4587","BK4081","AIPO","ISBC","CHAT","EMA","BK7067","AI","AIYY","BK4585","AGIX","ARTY","CUV.AU","BK4528"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629689980","title":"Clinuvel plans Phase III CUV107 vitiligo trial of Scenesse plus NB-UVB vs NB-UVB","url":"https://stock-news.laohu8.com/highlight/detail?id=2629689980","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2629689980?lang=en_us&edition=fundamental","pubTime":"2026-04-24 11:46","pubTimestamp":1777002368,"startTime":"0","endTime":"0","summary":"Clinuvel received final European Medicines Agency scientific advice on design of pivotal Phase III CUV107 study testing SCENESSE as systemic treatment for non-segmental vitiligo.Trial results have not been presented; study is slated to start in 2H 2026.CUV107 will compare SCENESSE used with narrowband UVB therapy versus narrowband UVB alone in 300 patients.EMA signaled it will weigh overall clinical package, including patient-reported assessments, when judging whether repigmentation benefits support marketing authorization.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Clinuvel Pharmaceuticals Limited published the original content used to generate this news brief on April 24, 2026, and is solely responsible for the information contai","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260424:nNDL59dwNM:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7508","CUV.AU","BK7067"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629898305","title":"BRIEF-Clinuvel Pharmaceuticals Receives Final EMA Scientific Advice For Pivotal Phase III Vitiligo Study","url":"https://stock-news.laohu8.com/highlight/detail?id=2629898305","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2629898305?lang=en_us&edition=fundamental","pubTime":"2026-04-24 09:29","pubTimestamp":1776994152,"startTime":"0","endTime":"0","summary":"BRIEF-Clinuvel Pharmaceuticals Receives Final EMA Scientific Advice For Pivotal Phase III Vitiligo StudyApril 24  - Clinuvel Pharmaceuticals Ltd CUV.AX:RECEIVES FINAL EMA SCIENTIFIC ADVICE FOR PIVOTAL PHASE III VITILIGO STUDYCUV107 STUDY TO COMMENCE IN 2H 2026Further company coverage: CUV.AX ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260424:nFWN4161BB:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7067","BK7508","CUV.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629862958","title":"Clinuvel Pharmaceuticals Set for Phase 3 Vitiligo Study After Final Advice From European Medicines Agency","url":"https://stock-news.laohu8.com/highlight/detail?id=2629862958","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2629862958?lang=en_us&edition=fundamental","pubTime":"2026-04-24 08:10","pubTimestamp":1776989406,"startTime":"0","endTime":"0","summary":"Clinuvel Pharmaceuticals (ASX:CUV) said the European Medicines Agency (EMA) has proposed evaluating the company's Scenesse drug for the treatment of systemic vitiligo based on a \"totality of evidence\"","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK7067","EMA.AU","MDCO","EMA","CUV.AU","BK4081","BK7129","BK7508"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629768861","title":"Clinuvel Pharmaceuticals Ltd -  Cuv107 Study to Commence in 2H 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2629768861","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2629768861?lang=en_us&edition=fundamental","pubTime":"2026-04-24 06:56","pubTimestamp":1776985001,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260423:nFWN4161BB:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7508","CUV.AU","BK7067"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629617518","title":"Clinuvel Pharmaceuticals Ltd - Receives Final Ema Scientific Advice for Pivotal Phase Iii Vitiligo Study","url":"https://stock-news.laohu8.com/highlight/detail?id=2629617518","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2629617518?lang=en_us&edition=fundamental","pubTime":"2026-04-24 06:56","pubTimestamp":1776985001,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260423:nFWN4161BB:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7067","BK7508","CUV.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629502869","title":"ASX Growth Companies With High Insider Ownership April 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2629502869","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2629502869?lang=en_us&edition=fundamental","pubTime":"2026-04-24 03:08","pubTimestamp":1776971318,"startTime":"0","endTime":"0","summary":"As the Australian market navigates a complex landscape marked by geopolitical tensions and fluctuating commodity prices, investors are keeping a close eye on growth companies with high insider ownership. In such an environment, stocks with significant insider stakes can be appealing due to the potential alignment of interests between company leaders and shareholders, offering a sense of confidence amidst global uncertainties.","market":"nz","thumbnail":"https://images.simplywall.st/asset/industry/2052000-choice1-main-header/1585186836557","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/2052000-choice1-main-header/1585186836557"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/au/materials/asx-ltr/liontown-shares/news/asx-growth-companies-with-high-insider-ownership-april-2026","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/au/materials/asx-ltr/liontown-shares/news/asx-growth-companies-with-high-insider-ownership-april-2026","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["FRS.AU","BK7143","BK7067","SPL.AU","LTR.AU","BK7095","TTT.AU","BK7501","BK7096","XKO.AU","AR1.AU","ASG.AU","SKS.AU","AV1.AU","CBO.AU","BK7504","BK7016","BK7508","MAU.AU","XAO.AU","BK7110","CUV.AU","IMA.AU","TOR.AU","BK7141","XJO.AU","BK7036","BK7104","BK7023"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627253355","title":"ASX Growth Companies With High Insider Ownership For April 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2627253355","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2627253355?lang=en_us&edition=fundamental","pubTime":"2026-04-16 03:08","pubTimestamp":1776280087,"startTime":"0","endTime":"0","summary":"As Australian shares continue to climb amid global uncertainties, including ongoing tensions in the Middle East and concerns about fuel shortages, investors are keenly observing how these factors might impact market dynamics. In such a volatile environment, growth companies with high insider ownership often attract attention due to the confidence insiders demonstrate in their business prospects, offering potential resilience and alignment of interests with shareholders.","market":"sg","thumbnail":"https://images.simplywall.st/asset/industry/2053000-choice2-main-header/1585186554136","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/2053000-choice2-main-header/1585186554136"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/au/materials/asx-smi/santana-minerals-shares/news/asx-growth-companies-with-high-insider-ownership-for-april-2-2","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/au/materials/asx-smi/santana-minerals-shares/news/asx-growth-companies-with-high-insider-ownership-for-april-2-2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK7067","CUV.AU","FEX.AU","IMA.AU","BK7129","SMI.AU","BK7508","AV1.AU","TTT.AU","BK7084","BK7095","BK7036","CIA.AU","BK7110","FRS.AU","BK7007","MAU.AU","AR1.AU","BK7104","TOR.AU","BK7016","CAT.AU","CYC.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627405380","title":"Clinuvel Phase III vitiligo trial tests afamelanotide with NB-UVB phototherapy","url":"https://stock-news.laohu8.com/highlight/detail?id=2627405380","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2627405380?lang=en_us&edition=fundamental","pubTime":"2026-04-15 14:22","pubTimestamp":1776234172,"startTime":"0","endTime":"0","summary":"Clinuvel highlighted interim patient case studies from its ongoing Phase III vitiligo trial CUV105 at AAD 2026, with results already presented at Global Vitiligo Foundation annual symposium during meeting.Case studies indicated afamelanotide with adjunct narrowband UVB supported repigmentation, including in patients with active disease.Follow-up observations suggested pigmentation durability in darker skin types for up to six months after treatment withdrawal, signaling potential for longer-lasting disease stability versus chronic immune-suppressing approaches.Afamelanotide remains unapproved for vitiligo globally, keeping regulatory outcome of CUV105 central to Clinuvel commercial strategy in dermatology.Clinuvel also introduced Vitiligo Visual Algorithm, an AI tool under refinement to standardize photographic assessment of pigmentation for tracking treatment progress.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260415:nNDL8vWt9Q:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","IE00BN0W2W23.USD","IE00BN0W2T93.GBP","IE00BKPKM429.USD","BK7067","LU2210149790.SGD","LU2095319765.USD","SG9999014005.SGD","BK7508","IE00B3QW5Z07.USD","LU0314104364.USD","CUV.AU","SG9999014039.USD","BK4585","LU2210150020.SGD","IE00BGHQF748.EUR","BK4112","SG9999014013.SGD","IE00B64PRP62.GBP","IE00BN0W2V16.EUR","SG9999014021.USD","NDAQ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627347969","title":"Clinuvel showcases vitiligo, photomedicine programs at American Academy of Dermatology meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2627347969","media":"Reuters","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2627347969?lang=en_us&edition=fundamental","pubTime":"2026-04-15 09:49","pubTimestamp":1776217789,"startTime":"0","endTime":"0","summary":"Clinuvel attended American Academy of Dermatology Annual Meeting 2026, presenting its photomedicine programs in Denver over five days to more than 20,000 delegates.Management highlighted Phase III CUV105 vitiligo study testing afamelanotide with NB-UVB, citing case data showing repigmentation at 20 weeks with pigmentation maintained up to six months post-treatment in darker skin types.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Clinuvel Pharmaceuticals Limited published the original content used to generate this news brief on April 15, 2026, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260415:nNDL8c8QlF:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7067","CUV.AU","BK7508"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627466852","title":"ASX Growth Stocks With High Insider Ownership And Up To 40% Earnings Growth","url":"https://stock-news.laohu8.com/highlight/detail?id=2627466852","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2627466852?lang=en_us&edition=fundamental","pubTime":"2026-04-14 03:08","pubTimestamp":1776107306,"startTime":"0","endTime":"0","summary":"As the Australian market grapples with geopolitical tensions and fluctuating indices, investors are increasingly seeking resilient opportunities amidst the uncertainty. In this environment, growth companies with high insider ownership can offer a compelling proposition, as they often demonstrate strong alignment between management and shareholder interests, potentially driving robust earnings growth even in challenging times.","market":"nz","thumbnail":"https://images.simplywall.st/asset/industry/2053000-choice2-main-header/1585186554136","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/2053000-choice2-main-header/1585186554136"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/au/materials/asx-alk/alkane-resources-shares/news/asx-growth-stocks-with-high-insider-ownership-and-up-to-40-e","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/au/materials/asx-alk/alkane-resources-shares/news/asx-growth-stocks-with-high-insider-ownership-and-up-to-40-e","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK7145","BK7016","TOR.AU","AR1.AU","ALK.AU","CYC.AU","BK7017","GLF.AU","BK7067","AEM.AU","FEX.AU","BK7095","XJO.AU","BK7129","BK7508","FRS.AU","AV1.AU","BK7007","CUV.AU","BK7506","XAO.AU","BK7104","IMA.AU","XKO.AU","MAU.AU","BK7110"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627481940","title":"Clinuvel Pharmaceuticals Says JPMorgan Increases Stake","url":"https://stock-news.laohu8.com/highlight/detail?id=2627481940","media":"MT Newswires Live","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2627481940?lang=en_us&edition=fundamental","pubTime":"2026-04-13 13:45","pubTimestamp":1776059147,"startTime":"0","endTime":"0","summary":"Clinuvel Pharmaceuticals (ASX:CUV) said JPMorgan Chase & Co. and its affiliates have increased their stake in the company on April 8 to 7.02% or 3.5 million shares from 5.57% or 2.8 million shares, according to a Monday Australian bourse filing.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["IE00BLSP4239.USD","LU2211815571.USD","LU1363072403.SGD","LU2237443549.SGD","LU1548497426.USD","LU0345770993.USD","IE00BKDWB100.SGD","LU1720051017.SGD","LU2552382058.USD","LU1244550577.SGD","SG9999002224.SGD","LU0345770308.USD","LU0211328371.USD","IE00BFXG1179.USD","LU0208291251.USD","LU0265550359.USD","LU0323591593.USD","CUV.AU","LU0345769128.USD","LU0820562030.AUD","LU1116320737.USD","JPO","LU1668664300.SGD","IE0034235295.USD","BK4588","LU2237443622.USD","LU2237443895.HKD","IE00B3S45H60.SGD","JPMO","LU0942090050.USD","LU2023250504.SGD","BK4581","IE00BLSP4452.SGD","LU0006306889.USD","LU1894683264.USD","BK4585","LU1629891620.HKD","LU2756315664.SGD","LU0689472784.USD","LU1032466523.USD","LU2237443465.HKD","LU1366192091.USD","LU1119994496.HKD","LU2242649171.HKD","LU2417539215.USD","LU2213496289.HKD","LU1261432733.SGD","LU0211326839.USD","BK7508","LU2357305700.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627093751","title":"ASX Growth Companies With High Insider Ownership In April 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2627093751","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2627093751?lang=en_us&edition=fundamental","pubTime":"2026-04-13 03:08","pubTimestamp":1776020881,"startTime":"0","endTime":"0","summary":"As the Australian market remains steady amidst global geopolitical developments, investors are keeping a close eye on growth companies with strong insider ownership that could offer resilience in uncertain times. In such a landscape, firms where insiders hold significant stakes may align their interests closely with shareholders, potentially providing stability and confidence to investors navigating these complex conditions.","market":"us","thumbnail":"https://images.simplywall.st/asset/industry/8041000-choice2-main-header/1585186556238","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/8041000-choice2-main-header/1585186556238"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/au/software/asx-eol/energy-one-shares/news/asx-growth-companies-with-high-insider-ownership-in-april-20","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/au/software/asx-eol/energy-one-shares/news/asx-growth-companies-with-high-insider-ownership-in-april-20","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["MAU.AU","BK7104","AV1.AU","CYC.AU","FEX.AU","BK7017","BK7007","AEM.AU","BK7016","CU6.AU","CUV.AU","IMA.AU","AR1.AU","BK7110","FRS.AU","TOR.AU","BK7067","BK7508","BK7129","BK7095","EOL.AU","BK7096"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2626275239","title":"3 ASX Growth Stocks Insiders Own With Up To 90% Earnings Growth","url":"https://stock-news.laohu8.com/highlight/detail?id=2626275239","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2626275239?lang=en_us&edition=fundamental","pubTime":"2026-04-09 03:10","pubTimestamp":1775675409,"startTime":"0","endTime":"0","summary":"As the Australian share market braces for potential geopolitical impacts, with recent developments in the Middle East influencing investor sentiment, the ASX 200 futures remain resiliently strong. In such an environment, growth companies with high insider ownership can offer a unique appeal, as they often indicate confidence from those closest to the business and can be particularly compelling amidst global uncertainties.","market":"us","thumbnail":"https://images.simplywall.st/asset/industry/2024000-choice2-main-header/1585186739035","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/2024000-choice2-main-header/1585186739035"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/au/materials/asx-ttt/titomic-shares/news/3-asx-growth-stocks-insiders-own-with-up-to-90-earnings-grow","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/au/materials/asx-ttt/titomic-shares/news/3-asx-growth-stocks-insiders-own-with-up-to-90-earnings-grow","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK7508","AV1.AU","MAU.AU","CGS.AU","FRS.AU","MPW.AU","BK7007","AR1.AU","TOR.AU","BK7036","FEX.AU","BK7016","IMA.AU","BK7067","BK7095","BK7088","BK7094","CYC.AU","EIQ.AU","BK7104","CUV.AU","BK7129","TTT.AU","BK7110"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624313520","title":"Australian Shares Fall Sharply; ASX Commits to Addressing Governance, Risk Management Shortcomings Flagged by ASIC","url":"https://stock-news.laohu8.com/highlight/detail?id=2624313520","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2624313520?lang=en_us&edition=fundamental","pubTime":"2026-04-02 13:31","pubTimestamp":1775107900,"startTime":"0","endTime":"0","summary":"Australian shares fell sharply on Thursday's close, the last trading day before the Easter break, after a speech by US President Donald Trump threatened further attacks on Iran.The S&P/ASX 200 Index r","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["ON","LU1854103824.USD","LU0124384867.USD","BK4107","XKO.AU","BK7505","BK7509","IE00BFMHRM44.USD","LU1861219969.SGD","LU2360107325.USD","IE00BZ199S13.USD","BK4141","LU0724618433.USD","LU1720051017.SGD","LU1548497426.USD","LU1978683503.SGD","ASIC","LU1861220033.SGD","BK7067","SM1.AU","XJO.AU","IE00BD6J9T35.USD","LU1854104046.USD","CUV.AU","XAO.AU","BK7039","ASX.AU","BK4605","LU2357305700.SGD","LU1720051108.HKD","LU1861214812.USD","BK7508","LU2298322129.HKD","LU0348723411.USD","LU1861215975.USD","BK4585","BK7141","BK4588","BK4512"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624818521","title":"Clinuvel Says Study Shows Repigmentation in Vitiligo Patients After 20 Weeks of Therapy With Drug Candidate; Shares Hit Eight-Year Low","url":"https://stock-news.laohu8.com/highlight/detail?id=2624818521","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2624818521?lang=en_us&edition=fundamental","pubTime":"2026-04-02 10:43","pubTimestamp":1775097809,"startTime":"0","endTime":"0","summary":"Clinuvel Pharmaceuticals (ASX:CUV) said patient case studies from its ongoing CUV105 study in vitiligo showed repigmentation after 20 weeks of therapy with its drug candidate afamelanotide and adjunct","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["CUV.AU","BK7067","BK7508"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":5,"pageCount":3,"totalSize":82,"code":"91000000","status":"200"}]}}